Gilead Sciences (NASDAQ:GILD) Receives “Hold” Rating from Robert W. Baird

Gilead Sciences (NASDAQ:GILD)‘s stock had its “hold” rating reaffirmed by equities research analysts at Robert W. Baird in a report released on Monday, TipRanks reports. They presently have a $76.00 target price on the biopharmaceutical company’s stock. Robert W. Baird’s target price suggests a potential downside of 1.22% from the stock’s current price.

Several other analysts have also issued reports on the stock. BidaskClub lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Wednesday, May 20th. Wolfe Research began coverage on shares of Gilead Sciences in a research report on Tuesday, March 31st. They issued a “market perform” rating and a $65.00 price target for the company. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $85.00 price target on shares of Gilead Sciences in a research report on Wednesday, May 13th. Morgan Stanley upped their price target on shares of Gilead Sciences from $75.00 to $77.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Finally, Royal Bank of Canada reiterated a “buy” rating and issued a $88.00 price target on shares of Gilead Sciences in a research report on Wednesday, June 3rd. Five analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and ten have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $79.65.

Shares of NASDAQ GILD opened at $76.94 on Monday. The firm has a 50 day moving average of $75.41 and a 200 day moving average of $72.02. The company has a current ratio of 3.04, a quick ratio of 2.92 and a debt-to-equity ratio of 1.00. The firm has a market capitalization of $96.51 billion, a price-to-earnings ratio of 19.78, a price-to-earnings-growth ratio of 3.37 and a beta of 0.68. Gilead Sciences has a 12-month low of $60.89 and a 12-month high of $85.97.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.11. The company had revenue of $5.55 billion during the quarter, compared to analyst estimates of $5.44 billion. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.67 earnings per share. Sell-side analysts predict that Gilead Sciences will post 6.4 EPS for the current year.

In related news, EVP Brett A. Pletcher sold 13,210 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the sale, the executive vice president now owns 27,204 shares of the company’s stock, valued at $2,155,372.92. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director John Francis Cogan sold 2,413 shares of the stock in a transaction on Monday, April 13th. The shares were sold at an average price of $75.90, for a total transaction of $183,146.70. Following the completion of the sale, the director now directly owns 57,273 shares in the company, valued at approximately $4,347,020.70. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 37,731 shares of company stock worth $3,008,736. 0.13% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Buckingham Asset Management LLC raised its stake in shares of Gilead Sciences by 2.3% in the first quarter. Buckingham Asset Management LLC now owns 5,911 shares of the biopharmaceutical company’s stock valued at $442,000 after acquiring an additional 131 shares during the period. Baldwin Brothers Inc. MA raised its stake in shares of Gilead Sciences by 63.3% in the first quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 136 shares during the period. Twin Focus Capital Partners LLC raised its stake in shares of Gilead Sciences by 2.1% in the first quarter. Twin Focus Capital Partners LLC now owns 6,537 shares of the biopharmaceutical company’s stock valued at $489,000 after acquiring an additional 137 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in shares of Gilead Sciences by 4.2% in the first quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 3,605 shares of the biopharmaceutical company’s stock valued at $270,000 after acquiring an additional 144 shares during the period. Finally, Institute for Wealth Management LLC. raised its stake in shares of Gilead Sciences by 1.3% in the fourth quarter. Institute for Wealth Management LLC. now owns 11,104 shares of the biopharmaceutical company’s stock valued at $722,000 after acquiring an additional 145 shares during the period. 80.15% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: Profit Margin

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.